CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, named its new Board of Directors led by co-founder Jérôme Koch, in line with recent bridge financing organized ...

Berlin (ots) - Der Frühling steht vor der Tür, doch die aktuelle Grippewelle hat Deutschland weiterhin fest im Griff. In der ...

Pfizer has disappointed investors for the past three years, but its low valuation could make it attractive now. Its sales may decline a bit in 2025, but management has been targeting long-term ...

Dr Paciaroni reports compensation from Pfizer Canada, Inc, iRhythm Technologies, Sanofi-Aventis US LLC, Daiichi Sankyo Europe GmbH, Boehringer Ingelheim, and Bristol Myers Squibb for other services.

Drugmaker Pfizer has sold its entire stake in Haleon for about £2.5 billion to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said today.

(Bloomberg) -- Pfizer Inc. raised about £2.55 billion ($3.3 billion) through the sale of its remaining 7.3% stake in Haleon Plc, culminating a years-long separation from the maker of Sensodyne ...

Pfizer PFE0.80%increase; green up pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total pay increase, according (PDF) to a securities filing. The CEO's ...

Arv­inas and Pfiz­er’s tar­get­ed pro­tein de­grad­er has not man­aged to dis­tin­guish it­self from oth­er, sim­i­lar breast can­cer drugs, ac­cord­ing to piv­otal da­ta re­ ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy ...